ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GERN Geron Corp

3.945
-0.135 (-3.31%)
Last Updated: 20:06:26
Delayed by 15 minutes
Share Name Share Symbol Market Type
Geron Corp NASDAQ:GERN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.135 -3.31% 3.945 3.94 3.95 4.20 3.84 4.14 7,371,443 20:06:26

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21/03/2019 12:00pm

GlobeNewswire Inc.


Geron (NASDAQ:GERN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Geron Charts.

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 78,400 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company.

The stock options were granted on March 20, 2019 at an exercise price of $1.77 per share, which is equal to the closing price of Geron common stock on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. The options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of a stock option agreement covering the grant and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

CONTACT:

Suzanne MessereInvestor and Media Relationsinvestor@geron.commedia@geron.com

CG Capital877-889-1972

1 Year Geron Chart

1 Year Geron Chart

1 Month Geron Chart

1 Month Geron Chart

Your Recent History

Delayed Upgrade Clock